JOHN GENTRY: Open Payments
NPI 1932351061 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$571 in 32 payments from 15 companies in 2025. Trend: 2023 $845 · 2024 $273 · 2025 $571
Food & beverage: $571
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 5 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $85 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Alkermes, Inc. | 2 | $50 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| ABBVIE INC. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| OWP Pharmaceuticals, Inc. | 1 | $22 |
| Indivior Inc. | 1 | $20 |
Products named: FANAPT, CAPLYTA, AUSTEDO XR, REXULTI, ARISTADA, Auvelity, VRAYLAR, TRINTELLIX.
Industry payments across GA — which companies pay providers there.
